Celu­lar­i­ty signs on to do con­tract re­search for Re­gen­eron

Celu­lar­i­ty an­nounced Tues­day morn­ing that it will do con­tract re­search for Re­gen­eron on the Tar­ry­town, NY-based com­pa­ny’s “off-the-shelf” CAR-T cell ther­a­pies. Af­ter a rough year, it’s an­oth­er way for Celu­lar­i­ty to fund its busi­ness.

Celu­lar­i­ty de­clined to share the fi­nan­cial de­tails of the con­tract. The ini­tial fo­cus of the work will be Re­gen­eron’s gam­ma delta CAR-T cell ther­a­py that is de­signed to at­tack sol­id tu­mors. Re­gen­eron is part­nered with Adicet Bio on Adicet’s gam­ma delta CAR-T ther­a­py, which they’ve been col­lab­o­rat­ing on since 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER